

Arushi Khurana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/308565/publications.pdf>

Version: 2024-02-01

37
papers

236
citations

1163117

8
h-index

1125743

13
g-index

37
all docs

37
docs citations

37
times ranked

260
citing authors

#	ARTICLE	IF	CITATIONS
1	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. <i>Radiotherapy and Oncology</i> , 2022, 166, 171-179.	0.6	27
2	Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. <i>Blood Advances</i> , 2021, 5, 2426-2437.	5.2	24
3	A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2757-2762.	5.2	19
4	Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. <i>Blood Advances</i> , 2021, 5, 1379-1387.	5.2	18
5	Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. <i>Journal of Hematology and Oncology</i> , 2022, 15, 36.	17.0	17
6	Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1641-1649.	1.6	16
7	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. <i>Leukemia and Lymphoma</i> , 2020, 61, 3351-3359.	1.3	14
8	Role of Microenvironment in Non-Hodgkin Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 206-216.	2.0	10
9	The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Blood Cancer Journal</i> , 2021, 11, 124.	6.2	9
10	Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2022, 23, 171-187.	3.0	9
11	Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2217-2222.	2.0	7
12	Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis. <i>American Journal of Hematology</i> , 2021, 96, E298-E301.	4.1	7
13	Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. <i>HemaSphere</i> , 2021, 5, e640.	2.7	7
14	Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel. <i>American Journal of Hematology</i> , 2021, 96, E427-E430.	4.1	7
15	Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1063-1074.	1.3	6
16	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. <i>Blood Cancer Journal</i> , 2021, 11, 133.	6.2	4
17	Lines of therapy before autologous stem cell transplant and CAR affect outcomes in aggressive Non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2021, 96, E386-E389.	4.1	4
18	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 568-568.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 1363-1368.	1.3	4
20	Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2020, 136, 29-30.	1.4	3
21	Metabolic PET/CT Analysis of Aggressive Non-Hodgkin Lymphoma Prior to Axicabtagene Ciloleucel CAR-T Infusion: Predictors of Progressive Disease, Survival, and Toxicity. <i>Blood</i> , 2021, 138, 2518-2518.	1.4	3
22	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021, 138, 2527-2527.	1.4	3
23	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.	1.4	2
24	Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	2
25	In-field recurrences in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CART).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7556-7556.	1.6	2
26	Characteristics of patients with myelodysplastic syndrome with balanced translocations. <i>British Journal of Haematology</i> , 2020, 190, 244-248.	2.5	1
27	Primary Ocular Lymphoma: A SEER Database Analysis of Patterns of Involvement and Outcomes. <i>Blood</i> , 2019, 134, 4013-4013.	1.4	1
28	Peak Absolute Lymphocyte Count Post CAR-T Is Associated with Clinical Response and Survival Outcome in Aggressive Lymphoma. <i>Blood</i> , 2021, 138, 3856-3856.	1.4	1
29	Polatuzumab Vedotin Use before Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Aggressive Lymphoma: A US Single Center Experience. <i>Blood</i> , 2021, 138, 3842-3842.	1.4	1
30	A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 2495-2495.	1.4	1
31	The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP. <i>Blood</i> , 2021, 138, 53-53.	1.4	1
32	Vaccine Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy. <i>Blood</i> , 2021, 138, 3857-3857.	1.4	1
33	Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020, 136, 30-30.	1.4	1
34	Reversing the restrictive trend in diffuse large B-cell lymphoma trial eligibility: it's time to open the gates!. <i>British Journal of Haematology</i> , 2021, 193, 697-698.	2.5	0
35	Impact of Histologic Type on Survival in Primary Parotid Lymphomas. <i>Blood</i> , 2019, 134, 5882-5882.	1.4	0
36	Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis. <i>Blood</i> , 2021, 138, 1451-1451.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Response to Bridging Therapy As a Predictor of Outcomes for Chimeric Antigen Receptor Therapy in Large B-Cell Lymphoma. Blood, 2021, 138, 3841-3841.	1.4	0